Zofenoprilat 

Zofenoprilat is an angiotensin-converting enzyme (ACE) inhibitor with an IC₅₀ of 1.7 nM. Zofenoprilat exerts cardioprotective and renoprotective effects by inhibiting angiotensin II expression and lowering blood pressure. Zofenoprilat promotes NO production and reduces endothelin-1 (ET-1) expression. Zofenoprilat decreases TNFα-induced ROS production and protects vascular endothelial function. Zofenoprilat regulates oxidative stress-related molecules and possesses antioxidant activity. Zofenoprilat can be used in studies related to hypertension and congestive heart failure^[1][2].

Zofenoprilat (10^-8 M; 8 h) reduces the spontaneous ET-1 secretion level of HUVECs by 42%^[2].
Zofenoprilat (10^-8 M; 8 h) increases NO_x production in HUVECs by 110%^[2].
Zofenoprilat (10^-8 M) more effectively reduces the production of reactive oxygen species (ROS) in TNFα-stimulated HUVECs than Captopril^[2].
Zofenoprilat (10^-8 M) significantly inhibits TNFα-induced GSH depletion in HUVECs^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

325.45

C₁₅H₁₉NO₃S₂

75176-37-3

Oil

Colorless to light yellow

SC[C@@H](C)C(N1[C@@H](C[C@@H](C1)SC2=CC=CC=C2)C(O)=O)=O

Room temperature in continental US; may vary elsewhere.

• [1]. Ranadive SA, et al. Relative lipophilicities and structural-pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors. Pharm Res. 1992;9(11):1480-1486.  [Content Brief]

  [2]. Desideri G, et al. Different effects of angiotensin converting enzyme inhibitors on endothelin-1 and nitric oxide balance in human vascular endothelial cells: evidence of an oxidant-sensitive pathway. Mediators Inflamm. 2008;2008:305087.  [Content Brief]